Age is a predictor for the recurrence of syncope in vasovagal syncope patients with a positive head-up tilt test

CURRENT STATUS: UNDER REVIEW

BMC Cardiovascular Disorders  BMC Series

Yongjuan Guo  gyj601@sina.com
Ningbo City First Hospital
Corresponding Author
ORCiD: 0000-0001-8576-6045

Xiaomin Chen
Ningbo City First Hospital

Tianze Zeng
Ningbo City First Hospital

Lin Wang
Ningbo City First Hospital

Lvwei Cen
Ningbo City First Hospital

DOI: 10.21203/rs.2.15970/v3

SUBJECT AREAS  Cardiothoracic Surgery

KEYWORDS  Age; Predictor; Recurrence of syncope; Vasovagal Syncope; Head-up tilt test
Abstract

BACKGROUND Valid predictors of the recurrence of syncope in
vasovagal syncope (VVS) patients with a positive head-up tilt test (HUTT) are
currently lacking. The goal of this study was to identify the predictive performance
of age for the recurrence of syncope in VVS patients with a positive
HUTT.

METHODS In total, 175 VVS patients with a positive HUTT were followed for 6
to 32 months, and ≥1 syncope episodes during follow-up was considered the
recurrence of syncope. The study population was divided into 2 groups, namely, a
recurrence of syncope group (44 patients) and a no recurrence of syncope group
(131 patients). The baseline clinical data, hemodynamic parameters and
classification of the vasovagal syncope on the HUTT were analyzed. Logistics
regression was used to analyze the effect size and confidence interval of age. A
receiver operating characteristic (ROC) analysis was used to assess the predictive
performance and investigate the predictive value of age by the area under the
curve (AUC).

RESULTS The age of recurrence of syncope group 60.0 (47.8, 66.0)
years was older than that of no recurrence of syncope group 53.0 (43.0, 62.0) years,
and there was a significant difference between the two groups (P < 0.05). The trend
of syncope recurrence changed with age and the logistics regression model adjusted
by sex showed that the elder was an increased risk of syncope recurrence in VVS
with positive HUTT [OR value: 1.03, 95% confidence interval (CI) 1.008 to 1.061 p <
0.05]. Age was a valid predictor for the recurrence of syncope in VVS patients with a
positive HUTT (AUC: 0.688; 95% CI 0.598 to 0.777 p < 0.05). The cut-off value was
53.5 years, and the sensitivity and specificity were 72.7% and 52.7%, respectively.

CONCLUSIONS Age may be a valid predictor for recurrence of syncope in VVS
patients with positive HUTT. The rate of recurrence of syncope increased with increasing age, especially in old female.

background

Syncope is a transient loss of consciousness due to a transient global hypoperfusion characterized by rapid onset, short duration, and spontaneous complete recovery. Pre-syncope prodrome includes dizziness, headache, chest tightness, shortness of breath, palpitations, sweating, pallor and nausea, blurred vision, nausea, abdominal discomfort and amaurosis[1]. Vasovagal syncope (VVS) is challenging to treat as a heterogeneous disorder. The quality of life and mental health of patients could be seriously affected by recurrent VVS [2,3]. Most clinical studies on the treatment of the recurrence of syncope in VVS patients, such as with drugs, were mainly based on head-up tilt test (HUTT) results and the Vasovagal Syncope classification, and then the results of studies were inconsistent[4,5,6,7,8]. Syncope which is severe and refractory to conservative treatment is usually dealt with medical or device therapy. Thus, the valid prediction of recurrent syncope is urgently needed to guide the choice of treatment options. Factors which can best predict the recurrence of syncope after a positive HUTT are little known, despite numerous randomized trials. Older adults usually affect Atypical vasovagal syncope, and many of them have little or no prodrome[9]. Sheldon R et al. found that the most powerful predictor of a recurrence of syncope was the logarithm of the number of preceding syncopal spells[10]. We investigated that whether age is an important factor affecting syncope recurrence in VVS patients.

methods
Subjects

In total, 479 inpatient and outpatients with suspected clinically neuro-mediated syncope (NMS) underwent a HUTT in Ningbo Hospital, Zhejiang University from April 2016 to June 2018; 265 patients were excluded due to incomplete data, not signing the informed consent, with a negative HUTT, diagnosed with thostatic hypotension or postural orthostatic tachycardia. 214 patients with a positive HUTT were diagnosed with VVS, which performed in accordance with 2018 ESC Guidelines for the diagnosis and management of syncope [1]. All VVS patients underwent a complete physical examination, chest X-ray, biochemical serum tests, echocardiography, and electroencephalography to exclude severe diseases related to the central nervous, cardiovascular, and metabolic systems. Then, they were followed for between 6 and 32 months. 3 patients were treated pharmacologically (small doses of metorol or theophylline drugs, per os), 2 patients received pacemaker treatment (just DDD pacemaker) and 34 patients were lost to follow-up during follow-up (figure 1). This study was approved by the ethics committee of ningbo first hospital and carried out in accordance with the declaration of helsinki.

The data for 175 patients with a median age of 55.0 years (44.0 to 63.0 years, range from 15 to 82 years), were finally enrolled in the analysis; data from patients who were lost to follow-up or received medication or pacing were excluded from the analysis.

HUTT [1]

preparation

HUTT was strictly performed in accordance with the protocol of the European Society of Cardiology. Cardiovascular active drug treatment should be stopped using for at least 5 half-life period. Drugs and foods were avoided before the test, if
not, which could affect normal autonomic nervous system function. HUTT were performed in a quiet, softly lit, temperature-controlled (20 ~ 25°C) room equipped with medical resuscitation facilities, such as defibrillation, apparatus atropine and other resuscitative drug. Ringer's solution was used to in patients who fasted for at least 4h by intravenous drip before HUTT. Clinical basic data of cerebrovascular diseases (including cerebral ischemia, cerebral infarction, epilepsy and so on), hypertension, cardiovascular disease, diabetes (including type 1 or type 2), natural course of disease and number of spells in lifetime were asked for offering.

**baseline HUTT**

Patients were secured to the electric st-721 head-up tilt test table with manual control board (Beijing kangjing taike medical device factory) and GE medical CASE series 12-lead synchronous ECG monitor and suntech blood pressure monitor were used for monitoring blood pressure, heart rate and rhythm. Barring a positive response or loss of consciousness, patients were tilted upright at 70° for 20min after lying supine for at least 10 minute with record supine systolic blood pressure, supine diastolic blood pressure, and heart rate. Symptoms, blood pressure, heart rate and rhythm were recorded every 5 minute and additionally recorded every 1 minute within the begging 3 minutes to rule out orthostatic hypotension during the test. Patients were returned to a supine position as soon as the positive response occurred. The test will be terminated if HUTT is positive in basic stage and will go on with sublingual nitroglycerin HUTT.

**sublingual nitroglycerin HUTT**

The test process of SNHUTT was the same as that in the basic stage after the sublingual nitroglycerin administration which the baseline HUTT-negative patients received. (3/4 tablet, 0.5mg/ tablet of shandong xinyi pharmaceutical co.LTD.)
absorption time: usually from 2 to 5 minutes).

**Diagnostic criteria**

Syncope or pre-syncope prodrome accompanied with any of decreases in blood pressure or changes of heart rate with an electrocardiogram showing any of sinus arrest and premature junctional contractions and atrioventricular block and cardiac arrest ≥ 3 seconds was a positive HUTT response characteristic.

**Positive response type for VVS(1)**

1. **Type 1 (mixed type)**

Type 1 is characterized as heart rate fall but not less than 40 beats per minute (bpm) for < 10 seconds at the time of syncope with or without asystole < 3 seconds. Blood pressure decreases prior to the heart rate falls.

2. **Type 2 (cardioinhibitory type) which is classified to 2 subtype.**

   Type 2A (without asystole)

   Type 2A is characterized as a ventricular rate below 40 bpm for longer than 10 seconds and asystole < 3 seconds. the blood pressure decrease occurs later than the heart rate fall.

   Type 2B (with asystole)

   Type 2B is characterized as that the asystole > 3 seconds occurs. The heart rate fall coincides with or precedes the blood pressure decrease.

3. **Type 3 (vasoinhibitory type)**

Type 3 is characterized as that SBP or mean pressure decrease ≥ 20 ~ 30 mmHg or systolic BP (SBP) is ≤ 60 ~ 80 mmHg (1 mmHg = 0.133 kPa). The heart rate does not fall more than 10% from its peak value at the time of syncope.

**Counseling and advice**

An overview of the causes of vasovagal syncope and its overall benign outcome
were informed to all patients who received advice about increasing dietary salt and fluid intake unless contraindicated. Patients were also coached on how to avoid situations that might provoke syncope such as fatigue, late night, emotional status et al. and requested for sitting down or lying to a supine position if unavoidable.

**Follow-up protocols**

The duration of follow-up ranged from 6 to 32 months after HUTT via telephone follow-up. We one by one telephoned all patients. The patients or their parents were required to confirm recurrent syncope, which was defined as ≥ 1 syncope or typical pre-syncope prodrome that occurred during the follow-up. Patients who underwent pacing or drug therapy, such as with metoprolol during follow-up were excluded. Recurrence of syncope is defined as the recurrence of ≥ 1 syncope or typical pre-syncope prodrome during follow-up.

**Statistical analysis**

All reported levels of significance are 2 sided. A P value≤0.05 was considered statistically significant. Statistical analysis was carried out with SPSS 23.0 software. Continuous variables with normal distributions are expressed as the mean ± standard deviation (SD), and comparisons of normally distributed parameters between two groups were performed with a t-test for independent samples. The nonnormally distributed parameters were reported as the median and interquartile range (25% to 75%) and compared by the Mann-Whitney U test. Categorical variables are reported as frequencies and percentages. The data were compared by the Pearson's chi-square test, and the exact probability method was used when the theoretical frequency was less than 20%. Logistics regression was used to analyze effect size and confidence interval of the individual or multiple factors with statistical significance for recurrence syncope according to the independent sample
t test or the Pearson's chi-square test. The predictive performance of age was evaluated by prediction probability. The ROC curve was utilized to evaluate the predictive value of the predictors and the AUC represented the predictive value. The 95% CI of AUC did not contain 0.5 or a P value < 0.05 confirmed that the factor was a reliable predictor of recurrent syncope in VVS patients with a positive HUTT. The optimal cutoff value was determined as the maximum of the Youden index, which was defined as the sensitivity plus specificity minus 1, where sensitivity and specificity were calculated as proportions.

results

Patient population

In total, 175 VVS patients were included in the analysis after excluding those lost to follow-up and those receiving drug therapy or pacing, and 5 of them were positive on the BHUTT. Forty four (25.1%) VVS patients had ≥ 1 recurrence of syncope during follow-up.

The baseline characteristics

The baseline characteristics of the two groups are shown in Table 1. The age of the recurrence of syncope group was older than that of the no recurrence of syncope group (P < 0.05). Other characteristics were not significantly different between groups (P > 0.05).

The HUTT characteristics

The HUTT characteristics of the two groups are shown in Table 2. None of the HUTT characteristics were significantly different between groups (P > 0.05).

The distribution of patients by months of follow-up

The distribution of patients by months of follow-up is shown in Figure 1; The
distribution was inconsistent between the two groups. The average rank of the data shown in table 2 was not significantly different between the groups (P > 0.05)

The trend of syncope recurrence changed with age

The study population were classified based on age into 8 groups (<20, 20 - 30, 31 - 40, 41 - 50, 51 - 60, 61 - 70, 71 - 80, and >80 years old), and the graph showed that the rate of syncope recurrence increased with age (Figure 2).

Predictive performance of age

Age, as well as sex, BMI, supine diastolic BP(all p<0.15 in univariate analysis) were included in the logistic regression analysis. Only age with statistical significance in univariate analysis (OR value 1.034, p=0.011) and sex (OR value 2.302, p=0.032) were independently associated with syncope recurrence in VVS with positive HUTT in the multivariable model (table 3).

The predictive ability of age according to the ROC curve

The ROC curve of age for the prediction recurrent syncope in VVS patients with a positive HUTT had an AUC of 0.688 (vs. the null hypothesis AUC of 0.5, 95%CI 0.598 to 0.777, p < 0.05). A cutoff value of 53.5 years for age yielded high sensitivity (72.7%) and specificity (52.7%) (Fig. 3).

discussion

The main finding of this study is that age is a valid predictor of the recurrence of syncope in VVS patients with a positive HUTT in the ensuing follow-up from 6 to 32 months. The cutoff value for age is 53.5 years. Age as a predictor of recurrent syncope fulfills all 3 criteria for the highest level of statistical significance according to single factor analysis, binary logistic regression, and receiver operating characteristic (ROC) curve analysis. In contrast, other factors, such as VASIS
classification and the number of syncope episodes, were not statistically significant. Vasovagal syncope (VVS) is often diagnosed by a HUTT and is known to have a benign prognosis; however, recurrent VVS can seriously affect the quality of life and mental health of patients, particularly older adults. Valid predictors for recurrence of syncope in VVS, especially in VVS patients with a positive HUTT, are very important for the design of efficient, economical, individualized treatment. Sumner GL et al. proposed that the number of syncope episodes in the year preceding presentation was the most powerful predictor of the time to the recurrence of syncope in a referral-based vasovagal syncope population[12]. There was a similar phenomenon in our study in that the rate of the number of ≥ 3 lifetime syncopal spells in the recurrence of syncope group tended to be higher than that in the no recurrence of syncope group (50.0% vs. 39.7%, respectively), although the difference was not significant. Another important finding was that age was significantly associated with the recurrence of syncope, and the results indicated that age is a valid predictor of the recurrence of syncope in VVS patients with a positive HUTT. The results may be attributed to the following: first, a fall in cardiac output in adults is the dominant hypotensive mechanism because the systemic vascular resistance always remains above the baseline levels[13]. Second, the rate of comorbidities in the recurrence of the syncope group tended to be higher than in the no recurrence of the syncope group (63.6% vs. 32.1%, respectively), although the difference was not significant. Third, Yamaguchi Y et al. proposed that among the patients with a positive HUTT, the recurrence rate of syncope after the HUTT was higher in those with LV dysfunction than in those with normal LV function[14], then the relatively older patients often have LV dysfunction because of cardiovascular comorbidities. Fourth, it is well-known that norepinephrine is the
junctional transmitter between sympathetic ganglion cells and effectors. Benditt DG et al. discovered greater a Epi/NE ratio in younger patients with syncope than in older patients during tilt-induced vasovagal syncope[15]. Finally, degenerative process results in autonomic nerve function damage, and the autonomic nervous system imbalance may be one of the underlying mechanisms[16]. Previous studies showed mixed results that the effects of drugs or pacing prevented vasovagal syncope [3,4,5,6,7]. A blinded, placebo controlled, multicenter, randomized study showed that the age of the patient and the need for isoproterenol to produce a positive tilt test did not predict subsequent significant benefit from metoprolol[5]. This was inconsistent with our findings. That the previous study enrolled younger subjects than those in our study may be the reason for this inconsistency [ mean age, 42±18 years vs. 53.0(43.0, 62.0) years, respectively]. Moreover, the subjects in our study had received nonpharmacological measures other than pacing, such as physiotherapeutic measures and psychological approaches. Our research further confirmed that β-adrenergic blockade may be effective in the prevention of relatively older VVS patients with positive HUTT and that pacemaker could reduce recurrent syncope in patients with recurrent vasovagal syncope in whom clinically relevant asystole had been documented by implantable loop recorder[7]. We believe that it is of great importance for clinical treatment and prognosis to detect valid predictors of recurrent syncope in vasovagal syncope(VVS) patients with a positive HUTT receiving nonpharmacological measures other than pacing based on our research.

**Limitations**

The present study also has limitations. First, our study was an open-label, observational, and single-center retrospective study, and selection bias is
inevitable. Second, the lack of data of on LV function resulted in the inability to stratify the population. Third, interval from the HUNT to the first recurrence of syncope was observed during follow-up, and the duration of follow-up varied. Fourth, that beat-to-beat non-invasive hemodynamic monitor was not used in our study, which makes observation of hemodynamic changes during syncope suboptimal. In addition, there are known limitations to the AUC statistical method. Randomized controlled studies are essential to assess the predictive value of age.

conclusions

Age may be a valid predictor for the recurrence of syncope in VVS patients with positive HUNT. The rate of recurrence of syncope increased with increasing age, especially in old female. VVS patients who were ≥ 53.5 -years- old with a positive HUNT had a greater possibility of the recurrence of syncope despite receiving nonpharmacological measures other than pacing. It should prompt more clinical vigilance and other considerations such as justification for continued antihypertensive therapy and active treatment of ventricular dysfunction.

abbreviations

VVS  vasovagal syncope
HUNT  head-up tilt test
BHUNT  baseline HUNT
SNHUNT  sublingual nitroglycerin HUNT
ROC  receiver operating characteristic
AUC  area under the curve
declarations

**Ethics approval and consent to participate**

The study has been granted ethics approval by the ethics committee of Ningbo first hospital and the protocol complied with the Declaration of Helsinki. All participants were fully informed by written consent and written informed consent was obtained from a parent or guardian for participants under 16 years old.

**Consent for publication**

not applicable.

**Availability of data and materials**

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

The study was supported by the Zhejiang Provincial Natural Science Foundation of China (LY19H020003, LY19H310002), the Ningbo Health Branding Subject Fund (PPXK2018-01), the Zhejiang Medical and Health Research Project (2020ZH032) and the Ningbo City Natural Science Foundation (2019A610339).

**Authors contributions**

YG participated in the design of the study, data collection and drafting the manuscript. XC conceived the study, participated in its design. TZ and LW and LC participated in the design of the study and data collection. All authors read and approved the final manuscript.

**Acknowledgements**
Not applicable.

references

1. 2018 ESC Guidelines for the diagnosis and management of syncope. J European Heart 2018; 39(21): 1883-1948 doi:10.1093/eurheartj/ehy037

2. Varga E, Worum F, Szabo Z, et al. Motor vehicle accident with complete loss of consciousness due to vasovagal syncope. Forensic Sci Int 2002; 130(2-3):156-9 PMID:12477637

3. Chen L, Li X, Todd O, et al. A clinical manifestation-based prediction of haemodynamic patterns of orthostatic intolerance in children: a multi-centre study. Cardiol Young 2014; 24(4):649-653. https://doi.org/10.1017/S1047951113000929

4. Raj SR, Faris PD, Semeniuk L, et al. Rationale for the Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Trial (POST5). J Am Heart 2016;174:89-94. https://doi.10.1016/j.ahj.2016.01.017

5. Ventura R, Maas R, Zeidler D, et al. A randomized and controlled pilot trial of beta-blockers for the treatment of recurrent syncope in patients with a positive or negative response to head-up tilt test. Pacing Clin Electrophysiol 2002; 25(5): 816 821-15. PMID:12049374

6. Sheldon R, Rose S, Connolly S. Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope; rationale and study design. Europace 2003; 5(1):71-75 https://doi:10.1053/eupc.2002.0284

7. Brignole M, Sutton R, Menozzi C, et al. (2006) Early application of an implantable loop recorder allows effective specific therapy in patients with
recurrent suspected neurally mediated syncope. Eur Heart J 2006 May;27(9):1085-92. https://doi:10.1093/eurheartj/ehi842

8. Brignole M, Menozzi C, Moya A, et al. (2012) Pacemaker therapy in patients with neurally-mediated syncope and documented asystole. Third international study on syncope of unknown etiology (ISSUE-3): a randomized trial. Circulation 2012; 125: 2566 -71. https://doi: 10.1161/CIRCULATIONAHA.111.082313. Epub 2012 May 7.

9. O'Dwyer C, Bennett K, Langan Y, et al. Amnesia for loss of consciousness is common in vasovagal syncope. Europace 2011;13(7):1040-5. https://doi: 10.1093/europace/eur069. Epub 2011 Mar 23.

10. Sheldon R, Rose S, Flanagan P, et al. Risk factors for syncope recurrence after a positive tilt-table test in patients with syncope. Circulation 1996;93(5):973- 81. PMID: 8598089.

11. Parry SW, Reeve P, Lawson J, et al. The Newcastle Protocols 2008: an Update on Head-up Tilt Table Testing and The Management of Vasovagal Syncope and Related Disorders. Heart. 2009;95(5):416-20. https://doi: 10.1136/hrt.2007.136457.

12. Sumner GL, Rose MS, Koshman ML, et al. Recent history of vasovagal syncope in a young, referral-based population is a stronger predictor of recurrent syncope than lifetime syncope burden. J Cardiovasc Electrophysiol. 2010 Dec;21(12):1375-80 https://doi: 10.1111/j.1540-8167.2010.01848.x.

13. Jardine DL, Wieling W, Brignole M, et al. The pathophysiology of the vasovagal response. Heart Rhythm 2018 Jun;15(6):921-929. https://doi: 10.1016/j.hrthm.2017.12.013. Epub 2017 Dec 12.
14. Yamaguchi Y, Mizumaki K, Nishida K, et al. Vasovagal syncope is associated with poor prognosis in patients with left ventricular dysfunction. Heart Vessels 2018 Apr;33(4):421-426. https://doi: 10.1007/s00380-017-1078-0.

15. Benditt DG1, Detloff BL, Adkisson WO, et al. Age-dependence of relative change in circulating epinephrine and norepinephrine concentrations during tilt-induced vasovagal syncope. Heart Rhythm 2012;9(11):1847-52. https://doi: 10.1016/j.hrthm.2012.07.028.

16. Grubb BP. Clinical practice. Neurocardiogenic syncope. N Engl J Med 2005;352(10):1004–1010. https://doi.org/10.1056/NEJMc042601

tables

| Table 1  | Baseline Characteristics of the Study Population and follow-up duration |
|----------|--------------------------------------------------------------------------|
| Cases(n=175) | Group A (n=44) | Group B (n=131) | t/ X² /Z value | P value |
| Males / females (n) | 13 /31 | 58 /73 | 2.964 | 0.085 |
| Age (yrs) | 60.0(47.8,66.0) | 53.0(43.0,62.0) | -2.346 | 0.019 |
| BMI (kg/m²) | 23.3±3.1 | 22.4±2.9 | 1.622 | 0.107 |
| Patients with comorbidities (n) | 28(63.6%) | 42(32.1%) | 13.683 | 0.000 |
| Hypertension (n) | 11(25.0%) | 36(27.5%) | 0.103 | 0.748 |
| Cardiovascular disease (n) | 3(6.8%) | 7(5.3%) | 0.000 | 1.000 |
| Diabetes (n) | 3(6.8%) | 4(3.1%) | 0.433 | 0.511 |
| Cerebrovascular disease (n) | 1(2.3%) | 3(1.5%) | 0.000 | 1.000 |
| Duration of symptoms (less than 2 years) | 25(56.8%) | 84(64.1%) | 0.748 | 0.387 |
| Number of spells in lifetime (more than 3 times) | 22(50.0%) | 52(39.7%) | 1.433 | 0.231 |
| Follow-up duration (months) | 18.0(14.0,25.0) | 16.0(11.0,23.0) | -1.482 | 0.138 |
Table 2  Baseline positive HUTT Characteristics of the Study Population

| Cases(n=175) | Group A (n=44) | Group B (n=131) | t/ X² value | P value |
|--------------|----------------|-----------------|-------------|---------|
| Positive BHUTT/ SNHUTT | 5/39 | 6/125 | 1.550 | 0.213 |
| HR (bpm) | 71.1±15.2 | 70.47±12.1 | 0.263 | 0.793 |
| Supine systolic BP (mmHg) | 126.3±19.1 | 124.7±18.8 | 0.482 | 0.630 |
| Supine diastolic BP (mmHg) | 78.3±9.9 | 75.5±11.2 | 1.469 | 0.144 |
| Supine heart rate (bpm) | 71.1±15.2 | 70.5±12.1 | 0.263 | 0.793 |
| Induced Syncope (n) | 19 | 58 | 0.016 | 0.899 |
| Arrhythmic events (n) | 4 | 18 | 0.648 | 0.421 |
| Type 1 (mixed type) (n) | 19 | 69 | 1.187 | 0.276 |
| Type 2(Cardioinhibitory type) (n) | 3 | 10 | 0.000 | 1.000 |
| type 2A (n) | 1 | 5 | 0.000 | 0.993 |
| Type 2B (n) | 2 | 5 | 0.000 | 1.000 |
| Type 3 (Vasodepressor type) (n) | 22 | 52 | 1.433 | 0.231 |

Table 3  Determinants of syncope recurrence in the Study Population

| Factor | B value | S.E value | Wald value | P value | Exp(B) 95%CI of Exp(B) |
|--------|---------|-----------|------------|---------|-----------------------|
| sex    | 0.834   | 0.389     | 4.598      | 0.032   | 2.30 1.07 4 - 4.93 2 |
| Age    | 0.034   | 0.013     | 6.427      | 0.011   | 1.03 1.008 - 1.061    |

CI confidence intervala

Figures
Figure 1

A study flowchart with included and excluded patients. NMS Neuro-Mediated Sync
Figure 2

the distribution of patients by months of follow-up
Age-Trend of syncope recurrence based on the percentage within each age group.
Figure 4

ROC curve of the predictive value of age for recurrent syncope by prediction prob